Benign Prostatic Hyperplasia Bph And Prostate Treatment Market

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market: Innovations in Non-invasive Treatment Alternatives to Provide Strong Impetus: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028

Ask The Analyst Customization Available Request Methodology

Prevalence of Benign Prostatic Hyperplasia Is on a Steady Rise 

According to the recent statistical data,

  • In the US, more than 8 million men are suffering from benign prostatic hyperplasia.

  • Globally, around 22 million men have been diagnosed with moderate-to-severe symptoms of benign prostatic hyperplasia.

  • The risk of having benign prostatic hyperplasia increases after the age of 40 by around 8%, and by the age of 90, the risk increases by as much as 60%.

The rising prevalence of benign prostatic hyperplasia (BPH) is the key factor driving the growth of the benign prostatic hyperplasia prostate treatment market. A few other factors such as diet, heredity, and lifestyle also play an important role in causing benign prostatic hyperplasia. With the increasingly aging population and a changing demographic profile in almost all societies, it is expected that benign prostatic hyperplasia prostate treatment will become a major challenge for all healthcare systems, and even more prevalent among men during the forecast period.

Nearly 50% men across the world by the age of 50 years and above are suffering from the medical condition – benign prostatic hyperplasia (BPH) prostate, according to a study published in the Canadian Journal of Urology. Stakeholders in the benign prostatic hyperplasia prostate treatment market are aiming to bolster their research & development activities to improve the efficacy of the existing medications. Thereby, the global market for benign prostatic hyperplasia prostate treatment is expected to witness steady growth, reaching US$ 25 billion in the coming decade.

Preeminent factors that are influencing the growth of the benign prostatic hyperplasia prostate treatment market include:

Advancements in Management of Benign Prostatic Hyperplasia

In the future, the demand for benign prostatic hyperplasia prostate treatment is expected to witness strong growth. Currently, a number of novel techniques are under clinical trials. Technology has played an important role in the latest advances in the management of benign prostatic hyperplasia prostate treatment.

Recently, a prostatic urethral lift has been considered to be one of the most favorable new techniques that have been performed in benign prostatic hyperplasia prostate treatment. In this technique, a novel mechanical implant is placed into the prostate by pulling the encroaching lobes of the prostate and improves a man’s urine flow.

Alpha-blockers are the first-line treatment that relaxes the prostate smooth muscle fibers. Excluding traditional oral medication, many studies have been carried out to inject drugs directly into the prostate. This has been stimulated by the increased use and efficiency of Botox treatment in the bladder. These initial trials of intraprostatic injections are expected to hold a promising influence on the overall development of benign prostatic hyperplasia prostate treatment market.

benign prostatic hyperplasia prostate treatment market

Mounting Costs of Benign Prostatic Hyperplasia Treatment

Financing healthcare costs due to the rising demand for benign prostatic hyperplasia prostate treatment is a great challenge. Basically, benign prostatic hyperplasia prostate treatment depends upon the severity of the condition and may involve pharmacotherapy and a number of surgical procedures. Hence, benign prostatic hyperplasia prostate treatment costs may vary dramatically. The latest UroLift System treatment is similar in effectiveness but costs twice as much as compared to other prostatic hyperplasia prostate treatments.

Cheaper and minimally invasive therapies cost nearly US$ 900, or slightly more expensive than the combination of drug therapy and generic drugs. In the US, a few years ago, annual direct and indirect costs to the private sector associated with benign prostatic hyperplasia treatment were estimated to be US$ 4 Bn. It has been observed that the costs tend to spike with the increasing number of aging men who are suffering from benign prostatic hyperplasia. High price point associated with the benign prostatic hyperplasia prostate treatment will continue to limit market growth in the long run.

Competition Analysis

The competitive landscape of benign prostatic hyperplasia prostate treatment market involves some of the industry behemoths, posing strong competition facing other smaller players. The report covers Pfizer, Inc., Valeant Pharmaceuticals Inc., Novartis AG, Bayer AG, Sanofi S.A., GlaxoSmithKline plc., Bristol-Myers Squibb and Company, Teva Pharmaceutical Industries Ltd, Mylan N.V., Merck & Co., Cardinal Health Inc., and Eli Lilly and Company among others.  

Definition

Benign prostatic hyperplasia prostate treatment includes a wide range of drugs and devices used for benign prostatic hyperplasia conditions. Drug-based therapy is the first line of treatment used widely for benign prostatic hyperplasia prostate treatment.

About the Report

The company conducted a research study on the benign prostatic hyperplasia prostate treatment market for the forecast period 2018 to 2028. This report provides a thorough assessment of opportunities in the benign prostatic hyperplasia prostate treatment market and provides an understanding of benign prostatic hyperplasia conditions, and lower urinary tract infections, and awareness level of benign prostatic hyperplasia prostate treatment and market competition in the benign prostatic hyperplasia prostate treatment market. The report provides thorough information regarding macroeconomic factors affecting the growth of the benign prostatic hyperplasia prostate treatment market.

Segmentation

The report offers a wide-ranging taxonomy of the benign prostatic hyperplasia prostate treatment market. The benign prostatic hyperplasia prostate treatment market has been segmented on the basis of treatment type, distribution channel, and region. The benign prostatic hyperplasia prostate treatment market has been segmented by treatment type into alpha-blockers, -alpha reductase inhibitors, phosphodiesterase-5 (PDE-5) Inhibitors, muscarinic receptor antagonist, and combination drugs. By distribution channel, the benign prostatic hyperplasia prostate treatment market has been segmented into institutional sales, retail sales, and online pharmacies.

Additional Questions Answered

Additional questions addressed in this benign prostatic hyperplasia prostate treatment market report are:

  • What is the revenue potential of the benign prostatic hyperplasia prostate treatment market across North America and Europe?

  • Who are the key players and what are their product portfolios in the benign prostatic hyperplasia prostate treatment market?

  • What are the major challenges impacting the growth of the benign prostatic hyperplasia prostate treatment market?

  • How is the involvement from key regulatory bodies shaping the growth of the benign prostatic hyperplasia prostate treatment market?

Research Methodology

The benign prostatic hyperplasia prostate treatment market has been estimated based on a supply-demand approach. The benign prostatic hyperplasia prostate treatment market was first studied based on the prevalence of benign prostatic hyperplasia conditions, diagnosis and treatment rate and availability of the drug in the different distribution channels across different regions/countries.

Further, qualitative factors impacting the benign prostatic hyperplasia prostate treatment market, such as awareness regarding benign prostatic hyperplasia prostate treatment and availability of drugs, average prices of drugs, key regulations and others, were studied.

Data analysis was validated through primary research methods, such as telephonic interviews, in-person interactions, surveys and viewpoints of experienced analysts & secondary research resources, such as trade journals, databases and verified paid sources. The research study on the benign prostatic hyperplasia prostate treatment market also provides the top trends and macro- and microeconomic factors influencing the benign prostatic hyperplasia prostate treatment market.

The company’s recent market study titled 'Benign Prostatic Hyperplasia Prostate Treatment Market: Global Industry Analysis 2013-2017 & Opportunity Assessment 2018-2028' comprises a comprehensive assessment of the key market dynamics. Through detailed research on the growth parameters of the benign prostatic hyperplasia prostate treatment market, growth forecasts of the market have been obtained with maximum accuracy.

The report features exclusive and significant factors that have a huge impact on the development of the benign prostatic hyperplasia prostate treatment market during the forecast period. These factors can aid market players in developing marketing and manufacturing strategies, and visualize maximum growth in the benign prostatic hyperplasia prostate treatment market during the forecast years. The report offers thorough information about the growth prospects of the benign prostatic hyperplasia prostate treatment market in a comprehensive way for a better understanding of readers.

Chapter 1 – Executive Summary

The report begins with the executive summary of the benign prostatic hyperplasia prostate treatment market, which includes a detailed summary of the key findings, statistics, and technology roadmap of the market. It also includes the market value (US$ million) estimations of leading segments in the benign prostatic hyperplasia prostate treatment market.

Chapter 2 – Market Introduction and Overview

The report summaries the detailed taxonomy and definitions, which are key to understanding the basic information regarding the benign prostatic hyperplasia prostate treatment market dynamics, key players, pricing analysis, and regulation policies of this market.

Chapter 3 – Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028 by Treatment Type

Based on treatment type, the benign prostatic hyperplasia prostate treatment market has been segmented into drugs and devices. The drugs segment of the benign prostatic hyperplasia prostate treatment market is segmented into alpha-blockers, alpha reductase inhibitors, phosphodiesterase-5 (PDE-5) inhibitors, muscarinic receptor antagonists, and combination drugs. The devices segment in the benign prostatic hyperplasia prostate treatment market is segmented into prostatic stents, suture base implant systems, and transurethral RF thermal therapy. Readers can find detailed information regarding the key market trends, developments, and market attractive analysis of the benign prostatic hyperplasia prostate treatment market based on treatment type.

Chapter 4 – Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028 by Distribution Channel

In terms of the distribution channel, the benign prostatic hyperplasia prostate treatment market is segmented into institutional sales, retail sales, and online pharmacies. Further, the institutional sales segment is sub-segmented into hospitals, ambulatory surgical centers, and specialty clinics. The retail sales segment is sub-segmented into retail pharmacies and drug stores.

Chapter 5 – Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028 by Region

This chapter provides detailed information regarding the current growth scenario of the benign prostatic hyperplasia prostate treatment market across various geographic regions such as North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East & Africa (MEA).

Chapter 6 – North America Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter includes a detailed analysis of the North America benign prostatic hyperplasia prostate treatment market growth, along with a country-wise assessment, including the U.S. and Canada. Readers can find detailed information regarding regional trends, macroeconomic factors, and market growth based on treatment type, distribution channel, and country, in the North America benign prostatic hyperplasia prostate treatment market.

Chapter 7 – Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter consists of the growth forecasts for the Latin America benign prostatic hyperplasia prostate treatment market in leading countries such as Brazil, Mexico, and the Rest of Latin America. Readers can also find detailed information regarding factors such as pricing analysis, regional trends, and growth factors that are influencing the growth of the Latin America benign prostatic hyperplasia prostate treatment market.

Chapter 8 – Europe Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

In this chapter, readers can find detailed information regarding key growth forecasts of the benign prostatic hyperplasia prostate treatment market based on applications in various European countries such as the U.K., Germany, France, Italy, Spain, Russia, and the Rest of Europe.

Chapter 9 – South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter includes the growth prospects of the benign prostatic hyperplasia prostate treatment market in leading South Asian countries such as India, Thailand, Indonesia, Malaysia, and the Rest of South Asia.

Chapter 10 – East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter includes the growth prospects of the benign prostatic hyperplasia prostate treatment market in leading East Asian countries such as China, Japan, and South Korea.

Chapter 11 – Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

In this chapter, readers can find detailed information regarding several parameters influencing the Oceania benign prostatic hyperplasia prostate treatment market during the forecast period 2018-2028. Australia and New Zealand are the leading countries in Oceania that are the prime subjects of assessment to obtain the growth prospects of the Oceania benign prostatic hyperplasia prostate treatment market.

Chapter 12 – MEA Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

Readers can find thorough information regarding the growth factors that are impacting the MEA benign prostatic hyperplasia prostate treatment market, and gain insights on how the benign prostatic hyperplasia prostate treatment market is likely to impact the main countries/region in MEA, such as GCC Countries, Turkey, North Africa, South Africa, and the Rest of MEA, over the forecast period 2018-2028.

Chapter 13 – Competition Landscape, Company Share, and Company Profiles

This chapter provides readers a wide-ranging list of all the prominent key players in the benign prostatic hyperplasia prostate treatment market, along with detailed information regarding each company, including company overview, offered products, revenue shares, key strategy, and recent company developments.

Chapter 14 – Assumptions and Acronyms

This chapter in the benign prostatic hyperplasia prostate treatment market report includes a list of assumptions and acronyms that provide a base to the statistics and information included in the report.

Chapter 15 – Research Methodology

This chapter in the benign prostatic hyperplasia prostate treatment market report provides readers with a detailed research methodology employed to obtain various conclusions and important qualitative and quantitative information regarding the benign prostatic hyperplasia prostate treatment market.

Benign Prostatic Hyperplasia Bph And Prostate Treatment Market Reports - Table of Contents

1. Executive Summary

     1.1. Market Overview

     1.2. Market Analysis

     1.3. Technology Roadmap

     1.4. FMI Analysis and Recommendations

2. Market Introduction

     2.1. Market Introduction

     2.2. Market Taxonomy

     2.3. Market Definition

     2.4. Inclusions and Exclusions

3. Benign Prostatic Hyperplasia Prostate Treatment Market Opportunity Analysis 

     3.1. Macro-Economic Factors

     3.2. Opportunity Analysis

4. Market Background

     4.1. Market Dynamics

           4.1.1. Drivers

           4.1.2. Restraints

           4.1.3. Key Trends

5. Key Inclusions

     5.1. Pipeline Analysis

     5.2. Prevalence and Treatment Seeking Population Analysis

6. Global Economic Outlook

     6.1. Gross Domestic Product by Region & Country, 2006 – 2021

7. Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Region

     7.1. Introduction / Key Findings

     7.2. Historical Market Size (US$ Mn) Trend Analysis by Region, 2013–2017

           7.2.1. North America

           7.2.2. Latin America

           7.2.3. Europe

           7.2.4. South Asia

           7.2.5. East Asia

           7.2.6. Oceania

           7.2.7. The Middle East and Africa

           7.2.8. Emerging Countries

     7.3. Market Size (US$ Mn) Forecast By Region, 2018–2028

     7.4. Market Attractiveness Analysis by Region

8. Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Treatment Type

     8.1. Introduction

     8.2. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2017

           8.2.1. Drugs

                    8.2.1.1. Alpha Blockers

                    8.2.1.2. 5-alpha Reductase Inhibitors

                    8.2.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    8.2.1.4. Muscarinic Receptor Antagonist (MRA)

                    8.2.1.5. Combination Drug

           8.2.2. Device

                    8.2.2.1. Prostatic Stents

                    8.2.2.2. Suture Base Implant Systems

                    8.2.2.3. Transurethral RF Thermal Therapy Devices

     8.3. Market Size (US$ Mn) Forecast By Treatment Type, 2018–2028

     8.4. Market Attractiveness Analysis by Treatment Type

9. Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channels

     9.1. Introduction

     9.2. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2017

           9.2.1. Institutional Sales

                    9.2.1.1. Hospital

                    9.2.1.2. Ambulatory Surgical Centers

                    9.2.1.3. Specialty Clinics

           9.2.2. Retail Sales

                    9.2.2.1. Retail Pharmacies

                    9.2.2.2. Drug Stores

           9.2.3. Online Pharmacies

     9.3. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028

     9.4. Market Attractiveness Analysis by Distribution Channels

10. North America Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028

     10.1. Introduction

     10.2. Historical Market Size (US$ Mn) Analysis by Country, 2013–2017

           10.2.1. U.S.

           10.2.2. Canada

     10.3. Market Size (US$ Mn) Forecast By Country, 2018–2028

     10.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2017

           10.4.1. Drugs

                    10.4.1.1. Alpha Blockers

                    10.4.1.2. 5-alpha Reductase Inhibitors

                    10.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    10.4.1.4. Muscarinic Receptor Antagonist (MRA)

                    10.4.1.5. Combination Drug

           10.4.2. Device

                    10.4.2.1. Prostatic Stents

                    10.4.2.2. Suture Base Implant Systems

                    10.4.2.3. Transurethral RF Thermal Therapy Devices

     10.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018–2028

     10.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2017

           10.6.1. Institutional Sales

                    10.6.1.1. Hospital

                    10.6.1.2. Ambulatory Surgical Centers

                    10.6.1.3. Specialty Clinics

           10.6.2. Retail Sales

                    10.6.2.1. Retail Pharmacies

                    10.6.2.2. Drug Stores

           10.6.3. Online Pharmacies

     10.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028

     10.8. Market Attractiveness Analysis

           10.8.1. By Country

           10.8.2. By Treatment Type

           10.8.3. By Distribution Channel

     10.9. Market Size and Forecast Factors

     10.10. Key Intensity Mapping

11. Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028

     11.1. Introduction

     11.2. Historical Market Size (US$ Mn) By Country, 2013–2017

           11.2.1. Brazil

           11.2.2. Mexico

           11.2.3. Rest of Latin America

     11.3. Market Size (US$ Mn) Forecast By Country, 2018–2028

     11.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2017

           11.4.1. Drugs

                    11.4.1.1. Alpha Blockers

                    11.4.1.2. 5-alpha Reductase Inhibitors

                    11.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    11.4.1.4. Muscarinic Receptor Antagonist (MRA)

                    11.4.1.5. Combination Drug

           11.4.2. Device

                    11.4.2.1. Prostatic Stents

                    11.4.2.2. Suture Base Implant Systems

                    11.4.2.3. Transurethral RF Thermal Therapy Devices

     11.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018–2028

     11.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2017

           11.6.1. Institutional Sales

                    11.6.1.1. Hospital

                    11.6.1.2. Ambulatory Surgical Centers

                    11.6.1.3. Specialty Clinics

           11.6.2. Retail Sales

                    11.6.2.1. Retail Pharmacies

                    11.6.2.2. Drug Stores

           11.6.3. Online Pharmacies

     11.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028

     11.8. Market Attractiveness Analysis

           11.8.1. By Country

           11.8.2. By Treatment Type

           11.8.3. By Distribution Channel

     11.9. Market Size and Forecast Factors

     11.10. Key Intensity Mapping

12. Europe Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028

     12.1. Introduction

     12.2. Historical Market Size (US$ Mn) Analysis by Country, 2013–2017

           12.2.1. Germany

           12.2.2. U.K.

           12.2.3. France

           12.2.4. Italy

           12.2.5. Russia

           12.2.6. Spain

           12.2.7. Rest of Europe

     12.3. Market Size (US$ Mn) Forecast By Country, 2018–2028

     12.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2017

           12.4.1. Drugs

                    12.4.1.1. Alpha Blockers

                    12.4.1.2. 5-alpha Reductase Inhibitors

                    12.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    12.4.1.4. Muscarinic Receptor Antagonist (MRA)

                    12.4.1.5. Combination Drug

           12.4.2. Device

                    12.4.2.1. Prostatic Stents

                    12.4.2.2. Suture Base Implant Systems

                    12.4.2.3. Transurethral RF Thermal Therapy Devices

     12.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018–2028

     12.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2017

           12.6.1. Institutional Sales

                    12.6.1.1. Hospital

                    12.6.1.2. Ambulatory Surgical Centers

                    12.6.1.3. Specialty Clinics

           12.6.2. Retail Sales

                    12.6.2.1. Retail Pharmacies

                    12.6.2.2. Drug Stores

           12.6.3. Online Pharmacies

     12.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028

     12.8. Market Attractiveness Analysis

           12.8.1. By Country

           12.8.2. By Treatment Type

           12.8.3. By Distribution Channel

     12.9. Market Size and Forecast Factors

     12.10. Key Intensity Mapping

13. South Asia Benign Prostatic Hyperplasia Prostate Treatment Analysis 2013–2017 and Forecast 2018–2028

     13.1. Introduction

     13.2. Historical Market Size (US$ Mn) By Country, 2013–2017

           13.2.1. India

           13.2.2. Thailand

           13.2.3. Indonesia

           13.2.4. Malaysia

           13.2.5. Rest of South Asia

     13.3. Market Size (US$ Mn) Forecast By Country, 2018–2028

     13.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2017

           13.4.1. Drugs

                    13.4.1.1. Alpha Blockers

                    13.4.1.2. 5-alpha Reductase Inhibitors

                    13.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    13.4.1.4. Muscarinic Receptor Antagonist (MRA)

                    13.4.1.5. Combination Drug

           13.4.2. Device

                    13.4.2.1. Prostatic Stents

                    13.4.2.2. Suture Base Implant Systems

               13.4.2.3. Transurethral RF Thermal Therapy Devices

     13.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018–2028

     13.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2017

           13.6.1. Institutional Sales

                    13.6.1.1. Hospital

                    13.6.1.2. Ambulatory Surgical Centers

                    13.6.1.3. Specialty Clinics

           13.6.2. Retail Sales

                    13.6.2.1. Retail Pharmacies

                    13.6.2.2. Drug Stores

13.6.3. Online Pharmacies

     13.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028

     13.8. Market Attractiveness Analysis

           13.8.1. By Country

           13.8.2. By Treatment Type

           13.8.3. By Distribution Channel

     13.9. Market Size and Forecast Factors

     13.10. Key Intensity Mapping

14. East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028

     14.1. Introduction

     14.2. Historical Market Size (US$ Mn) By Country, 2013–2017

           14.2.1. China

           14.2.2. Japan

           14.2.3. South Korea

     14.3. Market Size (US$ Mn) Forecast By Country, 2018–2028

     14.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2017

           14.4.1. Drugs

                    14.4.1.1. Alpha Blockers

                    14.4.1.2. 5-alpha Reductase Inhibitors

                    14.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    14.4.1.4. Muscarinic Receptor Antagonist (MRA)

                    14.4.1.5. Combination Drug

           14.4.2. Device

                    14.4.2.1. Prostatic Stents

                    14.4.2.2. Suture Base Implant Systems

                    14.4.2.3. Transurethral RF Thermal Therapy Devices

     14.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018–2028

     14.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2017

           14.6.1. Institutional Sales

                    14.6.1.1. Hospital

                    14.6.1.2. Ambulatory Surgical Centers

                    14.6.1.3. Specialty Clinics

           14.6.2. Retail Sales

                    14.6.2.1. Retail Pharmacies

                    14.6.2.2. Drug Stores

           14.6.3. Online Pharmacies

     14.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028

     14.8. Market Attractiveness Analysis

           14.8.1. By Country

           14.8.2. By Treatment Type

           14.8.3. By Distribution Channel

     14.9. Market Size and Forecast Factors

     14.10. Key Intensity Mapping

15. Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028

     15.1. Introduction

     15.2. Historical Market Size (US$ Mn) By Country, 2013–2017

           15.2.1. Australia

           15.2.2. New Zealand

     15.3. Market Size (US$ Mn) Forecast By Country, 2018–2028

     15.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013–2017

           15.4.1. Drugs

                    15.4.1.1. Alpha Blockers

                    15.4.1.2. 5-alpha Reductase Inhibitors

                    15.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    15.4.1.4. Muscarinic Receptor Antagonist (MRA)

                    15.4.1.5. Combination Drug

           15.4.2. Device

                    15.4.2.1. Prostatic Stents

                    15.4.2.2. Suture Base Implant Systems

                    15.4.2.3. Transurethral RF Thermal Therapy Devices

     15.5. Market Size (US$ Mn)  Forecast By Treatment Type, 2018–2028

     15.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2017

           15.6.1. Institutional Sales

                    15.6.1.1. Hospital

                    15.6.1.2. Ambulatory Surgical Centers

                    15.6.1.3. Specialty Clinics

           15.6.2. Retail Sales

                    15.6.2.1. Retail Pharmacies

                    15.6.2.2. Drug Stores

           15.6.3. Online Pharmacies

     15.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028

     15.8. Market Attractiveness Analysis

           15.8.1. By Country

           15.8.2. By Treatment Type

           15.8.3. By Distribution Channel

     15.9. Market Size and Forecast Factors

     15.10. Key Intensity Mapping

16. MEA Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028

     16.1. Introduction

     16.2. Historical Market Size (US$ Mn) By Country, 2013–2017

           16.2.1. GCC Countries

           16.2.2. Turkey

           16.2.3. South Africa

           16.2.4. North Africa

           16.2.5. Rest of MEA

     16.3. Market Size (US$ Mn) Forecast By Country, 2018–2028

     16.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013–2017

           16.4.1. Drugs

                    16.4.1.1. Alpha Blockers

                    16.4.1.2. 5-alpha Reductase Inhibitors

                    16.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    16.4.1.4. Muscarinic Receptor Antagonist (MRA)

                    16.4.1.5. Combination Drug

           16.4.2. Device

                    16.4.2.1. Prostatic Stents

                    16.4.2.2. Suture Base Implant Systems

                    16.4.2.3. Transurethral RF Thermal Therapy Devices

     16.5. Market Size (US$ Mn)  Forecast By Treatment Type, 2018–2028

     16.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2017

           16.6.1. Institutional Sales

                    16.6.1.1. Hospital

                    16.6.1.2. Ambulatory Surgical Centers

                    16.6.1.3. Specialty Clinics

           16.6.2. Retail Sales

                    16.6.2.1. Retail Pharmacies

                    16.6.2.2. Drug Stores

           16.6.3. Online Pharmacies

     16.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028

     16.8. Market Attractiveness Analysis

           16.8.1. By Country

           16.8.2. By Treatment Type

           16.8.3. By Distribution Channel

     16.9. Market Size and Forecast Factors

     16.10. Key Intensity Mapping

17. Emerging Countries Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028

     17.1. Introduction

     17.2. Historical Market Size (US$ Mn) By Country, 2013–2017

           17.2.1. China

           17.2.2. Brazil

           17.2.3. South Africa

     17.3. Market Size (US$ Mn) Forecast By Country, 2018–2028

     17.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013–2017

           17.4.1. Drugs

                    17.4.1.1. Alpha Blockers

                    17.4.1.2. 5-alpha Reductase Inhibitors

                    17.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    17.4.1.4. Muscarinic Receptor Antagonist (MRA)

                    17.4.1.5. Combination Drug

           17.4.2. Device

                    17.4.2.1. Prostatic Stents

                    17.4.2.2. Suture Base Implant Systems

                    17.4.2.3. Transurethral RF Thermal Therapy Devices

     17.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018–2028

     17.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2017

           17.6.1. Institutional Sales

                    17.6.1.1. Hospital

                    17.6.1.2. Ambulatory Surgical Centers

                    17.6.1.3. Specialty Clinics

           17.6.2. Retail Sales

                    17.6.2.1. Retail Pharmacies

                    17.6.2.2. Drug Stores

           17.6.3. Online Pharmacies

     17.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028

     17.8. Market Attractiveness Analysis

           17.8.1. By Country

           17.8.2. By Treatment Type

           17.8.3. By Distribution Channel

     17.9. Market Size and Forecast Factors

     17.10. Key Intensity Mapping

18. Competitive Landscape

     18.1. Competition Dashboard

     18.2. Company Deep Dive

           18.2.1. Pfizer, Inc.

                    18.2.1.1. Company Overview

                    18.2.1.2. Product Portfolio

                    18.2.1.3. Key Financials and Y-O-Y Growth

                    18.2.1.4. Key Development and Strategy

           18.2.2. NxThera Inc.

                    18.2.2.1. Company Overview

                    18.2.2.2. Product Portfolio

                    18.2.2.3. Key Financials and Y-O-Y Growth

                    18.2.2.4. Key Development and Strategy

           18.2.3. NeoTract, Inc.

                    18.2.3.1. Company Overview

                    18.2.3.2. Product Portfolio

                    18.2.3.3. Key Financials and Y-O-Y Growth

                    18.2.3.4. Key Development and Strategy

           18.2.4. Sanofi S.A.

                    18.2.4.1. Company Overview

                    18.2.4.2. Product Portfolio

                    18.2.4.3. Key Financials and Y-O-Y Growth

                    18.2.4.4. Key Development and Strategy

           18.2.5. GlaxoSmithKline plc.

                    18.2.5.1. Company Overview

                    18.2.5.2. Product Portfolio

                    18.2.5.3. Key Financials and Y-O-Y Growth

                    18.2.5.4. Key Development and Strategy

           18.2.6. Allergan plc.

                    18.2.6.1. Company Overview

                    18.2.6.2. Product Portfolio

                    18.2.6.3. Key Financials and Y-O-Y Growth

                    18.2.6.4. Key Development and Strategy

           18.2.7. Teva Pharmaceutical Industries Ltd

                    18.2.7.1. Company Overview

                    18.2.7.2. Product Portfolio

                    18.2.7.3. Key Financials and Y-O-Y Growth

                    18.2.7.4. Key Development and Strategy

           18.2.8. Mylan N.V.

                    18.2.8.1. Company Overview

                    18.2.8.2. Product Portfolio

                    18.2.8.3. Key Financials and Y-O-Y Growth

                    18.2.8.4. Key Development and Strategy

           18.2.9. Eli Lilly and Company

                    18.2.9.1. Company Overview

                    18.2.9.2. Product Portfolio

                    18.2.9.3. Key Financials and Y-O-Y Growth

                    18.2.9.4. Key Development and Strategy

           18.2.10. Cardinal Health Inc.

                    18.2.10.1. Company Overview

                    18.2.10.2. Product Portfolio

                    18.2.10.3. Key Financials and Y-O-Y Growth

                    18.2.10.4. Key Development and Strategy

19. Assumptions and Acronyms Used 

20. Research Methodology

Benign Prostatic Hyperplasia Bph And Prostate Treatment Market Reports - List of Tables

Table 1: Expenditure on Health (% of GDP) by Country, 2016-2021

Table 2: Expenditure on Health (% of GDP) by Country, 2016-2021

Table 3: Global Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Region

Table 4: Global Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Treatment

Table 5: Global Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Table 6: North America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Country

Table 7: North America Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Treatment

Table 8: North America Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Table 9: Latin America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Country

Table 10: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Treatment

Table 11: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Table 12: Europe Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Country

Table 13: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Treatment

Table 14: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Table 15: South Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Country

Table 16: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Treatment

Table 17: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Table 18: East Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Country

Table 19: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Treatment

Table 20: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Table 21: Oceania Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Country

Table 22: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Treatment

Table 23: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Table 24: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Country

Table 25: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Treatment

Table 26: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Table 27: China Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Treatment

Table 28: China Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Table 29: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Treatment

Table 30: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Table 31: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Treatment

Table 32: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Benign Prostatic Hyperplasia Bph And Prostate Treatment Market Reports - List of Figures

Figure 1: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2017A

Figure 2: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2017A

Figure 3: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2017A

Figure 4: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2017A

Figure 5: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2017A

Figure 6: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2017A

Figure 7a: World GDP (Nominal) by Selected Economies, 2017

Figure 7b: Global Healthcare Expenditure in US$ Bn (2013–2020)

Figure 8: Global Benign Prostatic Hyperplasia Prostate Treatment Market Value (US$ Mn), By Region, 2018E & 2028F

Figure 9: Global Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Region, 2018E

Figure 10: Global Benign Prostatic Hyperplasia Prostate Treatment Market Value (US$ Mn), By Treatment, 2018E & 2028F

Figure 11: Global Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2018E

Figure 12: Global Benign Prostatic Hyperplasia Prostate Treatment Market Value (US$ Mn), By Distribution Channel, 2018E & 2028F

Figure 13: Global Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2018E

Figure 14: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2017A

Figure 15: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2017A

Figure 16: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2017A

Figure 17: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2017A

Figure 18: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2017A

Figure 19: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2017A

Figure 019: Brazil Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 20: North America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2017

Figure 21: North America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 22: North America Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2018E

Figure 23: North America Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2018E

Figure 24: North America Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2018E

Figure 25: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2017A

Figure 26: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2017A

Figure 27: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2017A

Figure 28: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2017A

Figure 29: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2017A

Figure 30: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2017A

Figure 31: Latin America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2017

Figure 32: Latin America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 33: Latin America Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2018E

Figure 34: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2018E

Figure 35: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2018E

Figure 36: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2017A

Figure 37: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2017A

Figure 38: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2017A

Figure 39: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2017A

Figure 40: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2017A

Figure 41: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2017A

Figure 42: Europe Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2017

Figure 43: Europe Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 44: Europe Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2018E

Figure 45: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2018E

Figure 46: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2018E

Figure 47: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2017A

Figure 48: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2017A

Figure 49: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2017A

Figure 50: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2017A

Figure 51: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2017A

Figure 52: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2017A

Figure 53: South Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2017

Figure 54: South Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 55: South Asia Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2018E

Figure 56: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2018E

Figure 57: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2018E

Figure 58: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2017A

Figure 59: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2017A

Figure 60: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2017A

Figure 61: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2017A

Figure 62: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2017A

Figure 63: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2017A

Figure 64: East Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2017

Figure 65: East Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 66: East Asia Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2018E

Figure 67: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2018E

Figure 68: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2018E

Figure 69: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2017A

Figure 70: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2017A

Figure 71: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2017A

Figure 72: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2017A

Figure 73: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2017A

Figure 74: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2017A

Figure 75: Oceania Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2017

Figure 76: Oceania Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 77: Oceania Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2018E

Figure 78: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2018E

Figure 79: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2018E

Figure 80: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2017A

Figure 81: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2017A

Figure 82: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2017A

Figure 83: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2017A

Figure 84: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2017A

Figure 85: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2017A

Figure 86: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2017

Figure 87: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 88: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2018E

Figure 89: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2018E

Figure 90: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2018E

Figure 91: Emerging Countries Benign Prostatic Hyperplasia Prostate Treatment Market Value Share (2017A)

Figure 92: Emerging Countries Benign Prostatic Hyperplasia Prostate Treatment Market Value (US$ Mn), By Key Countries, 2017A-2028E

Figure 93: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2017A

Figure 94: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2017A

Figure 95: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2017A

Figure 96: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2017A

Figure 97: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2017A

Figure 98: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2017A

Figure 99: China Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2017

Figure 100: China Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 101: China Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2018E

Figure 102: China Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2018E

Figure 103: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2017A

Figure 104: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2017A

Figure 105: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2017A

Figure 105: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2017A

Figure 106: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2017A

Figure 107: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2017A

Figure 108: Brazil Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2017

Figure 110: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2018E

Figure 111: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2018E

Figure 112: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2017A

Figure 113: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2017A

Figure 114: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2017A

Figure 115: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2017A

Figure 116: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2017A

Figure 117: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2017A

Figure 118: South Africa Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2017

Figure 119: South Africa Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 120: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2018E

Figure 121: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2018E